Hemab Therapeutics Holdings, Inc.
COAG evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for COAG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · COAG
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, with lead asset sutacimig in Phase 1/2 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, and HMB-002 in Phase 1/2 for Von Willebrand Disease.
Key risk: No approved products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials for Hemab Therapeutics Holdings, Inc..
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, with lead asset sutacimig in Phase 1/2 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, and HMB-002 in Phase 1/2 for Von Willebrand Disease.
- Lead asset sutacimig is a bispecific antibody in Phase 1/2 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency [sec_mda · as of 2026-08-11].
- Second clinical-stage asset HMB-002 is a monovalent antibody in Phase 1/2 for Von Willebrand Disease [sec_mda · as of 2026-08-11].
- Cash and equivalents of $237.4M as of 2026-06-30 [sec].
- Net income of -$24.1M for the six months ended 2026-06-30 [sec].
- Accumulated deficit of $228.7M as of 2026-06-30 [sec_mda · as of 2026-08-11].
What works
- Multiple clinical-stage assets targeting rare coagulation disorders with high unmet need, including Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease [sec_mda · as of 2026-08-11].
- Cash position of $237.4M as of 2026-06-30 provides runway to advance ongoing and planned clinical trials [sec].
- Anticipated multiple value-driving clinical data events in 2026, 2027 and beyond [sec_mda · as of 2026-08-11].
What to weigh
- Accumulated deficit of $228.7M as of 2026-06-30 and expectation of continued significant operating losses [sec_mda · as of 2026-08-11].
- Negative shareholders' equity of -$176.6M as of 2026-06-30 [sec].
- All product candidates are in early-to-mid stage clinical development with no approved products, and expenses are expected to increase substantially as trials advance [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Lead asset sutacimig is in Phase 1/2 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency.
“Our lead asset, sutacimig, is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency.”
SEC MD&A · August 11, 2026
HMB-002 is in Phase 1/2 for Von Willebrand Disease.
“Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development”
SEC MD&A · August 11, 2026
Accumulated deficit as of June 30, 2026.
“As of June 30, 2026, we had an accumulated deficit of $228.7 million.”
SEC MD&A · August 11, 2026
Company expects expenses to increase substantially as it advances clinical programs.
“We expect to continue to incur significant operating expenses and net losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: • continue to advance the clinical development of our product candidates”
SEC MD&A · August 11, 2026
Risks & what to watch (4)›
Key risks
- No approved products — All product candidates are in clinical development; no products have been approved for marketing [sec_mda · as of 2026-08-11].
- Significant accumulated deficit — Accumulated deficit of $228.7M as of 2026-06-30, with continued losses expected [sec_mda · as of 2026-08-11].
- Negative shareholders' equity — Shareholders' equity of -$176.6M as of 2026-06-30 indicates financial risk [sec].
- Dependence on clinical trial success — Future depends on successful completion of clinical trials for sutacimig, HMB-002, and HMB-003 [sec_mda · as of 2026-08-11].
What to watch
- Clinical data readouts for sutacimig in Glanzmann thrombasthenia and Factor VII deficiency anticipated in 2026-2027 [sec_mda · as of 2026-08-11].
- Clinical data readouts for HMB-002 in Von Willebrand Disease [sec_mda · as of 2026-08-11].
- Initiation of planned Phase 3 trial for sutacimig in Glanzmann thrombasthenia [sec_mda · as of 2026-08-11].
- Initiation of clinical trials for HMB-003 in heavy menstrual bleeding [sec_mda · as of 2026-08-11].
Sources: SEC filings · SEC MD&A · Generated August 21, 2026 · How we verify sources →
Run Hemab Therapeutics Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Hemab Therapeutics Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
59.4 months
D/E 0.03 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
16 buys · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Hemab Therapeutics Holdings, Inc.?
Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company developing therapies for blood coagulation disorders, with lead asset sutacimig in Phase 1/2 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, and HMB-002 in Phase 1/2 for Von Willebrand Disease.
What is Hemab Therapeutics Holdings, Inc.'s lead drug candidate?
Hemab Therapeutics Holdings, Inc.'s most advanced tracked candidate is sutacimig (Phase 2) for Congenital Factor VII Deficiency.
Who is the CEO of Hemab Therapeutics Holdings, Inc.?
Dr. Benny Sorensen M.D., Ph.D. is the chief executive officer of Hemab Therapeutics Holdings, Inc. (COAG).
Where is Hemab Therapeutics Holdings, Inc. headquartered?
Hemab Therapeutics Holdings, Inc. (COAG) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Hemab Therapeutics Holdings, Inc. focus on?
Hemab Therapeutics Holdings, Inc. develops therapies across Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.